Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Gilead Sciences Earnings Call: Key Takeaways

Gilead delivered record 16% base business growth driven by HIV and Oncology, though management faces a significant $1.5 billion revenue headwind in 2028 due to Medicare price setting for Biktarvy.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthHIV up 18% to $6.2B; Oncology/Trodelvy up 42% to $506M.
Mgmt ConfidenceHigh confidence in 2028 growth despite $1.5B Biktarvy headwind.
Demand VisibilityBiktarvy reached 53% US share; Yastugo on track for $1B annually.
Margin TrendsProduct gross margin 88%; operating margin 50% in Q3 2026.
Op. LeverageOperating margin in top quartile of peer group due to expense discipline.
Pricing PowerHigher average realized price in HIV; Medicare price setting limits Biktarvy power.
Vol vs PriceGrowth driven by higher demand, realized price, and favorable inventory dynamics.
Segment GrowthBase business up 16%; Cell Therapy down 18% due to competition.
New ClientsAcquiring oral IL-23R inhibitor from Pep-Star; BioNTech and Vera collaborations.
Capex & Debt$1.4B returned to shareholders; $1.4B upfront for Pep-Star and Vera deals.
RegulatoryBiktarvy MFP set at $2,600; Anito-cel PDUFA date December 23, 2026.
CommentaryManagement opposes IRA policies, citing a 'pill penalty' on small molecules.
New LaunchesBixlenvo launched August 2026; Anito-cel launch preparations for late 2026.

Growth

Base business sales rose 16% to $8.2 billion; HIV sales grew 18% to $6.2 billion.

Outlook

Raised 2026 base business revenue guidance to $30.7-$31.0 billion; expects 2028 total revenue growth.

Risks

Biktarvy Medicare price set at $2,600, a 38% discount, causing $1.5 billion 2028 revenue impact.

Source

The company's earnings call, NASDAQ: GILD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Gilead Sciences, Inc.: key numbers

Share price
$167.58Close, Nov 16
Market cap
$208B
Shares outstanding
1.24BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Gilead Sciences, Inc.

All →
3:44 PM ET Form 4
Insider Selling

Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock

Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).

Value
$1.76M
Shares
10,376
Average price
$169.76
Holding change
-13.0%
Trade date
Nov 12, 2026
7:20 PM ET Form 4
Insider Selling

Gilead Sciences EVP Gen Counsel, Legal & Comp Wettan Keeley M. Cain Sells $558K of Stock

Wettan Keeley M. Cain, EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Gilead Sciences, Inc. at $164.11 a share, worth $558K in total on Nov 6, 2026. Shares held after the trade: 5,360 (-38.8%).

Value
$558K
Shares
3,399
Price
$164.11
Role
EVP Gen Counsel, Legal & Comp
Holding change
-38.8%
Trade date
Nov 6, 2026
5:16 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $19.7M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 112,429 shares of Gilead Sciences, Inc. at $175.16 to $175.17 a share (average $175.16) in 2 transactions, worth $19.7M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 551,683 (-1.7%).

Value
$19.7M
Shares
112,429
Average price
$175.16
Role
Chairman & CEO
Holding change
-1.7%
Trade date
Nov 4, 2026 to Nov 5, 2026
7:15 PM ET Form 4
Insider Selling

Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock

Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).

Value
$5.33M
Shares
30,881
Average price
$172.57
Role
Chairman & CEO
Holding change
-0.4%
Trade date
Oct 30, 2026 to Nov 2, 2026
6:09 AM ET 10-Q
Financial Results ▶ Call

Gilead Sciences Q3 2026 Results: Net Income $2.43B, Down 20.4% YoY

Gilead Sciences reported total revenues of $8.3 billion for the third quarter of 2026, driven by $8.29 billion in product sales. Despite a profitable third quarter, the company recorded a net loss of $6.05 billion for the first nine months of 2026, primarily due to $11.3 billion in acquired in-process research and development expenses.

Key figure
Net income $2.43B · -20.4% YoY
4:05 PM ET 8-K
Financial Results

Gilead Sciences Financial Results

Gilead Sciences reported third-quarter 2026 financial results, featuring a 13% increase in total product sales to $8.3 billion, driven by strong performance in its HIV portfolio. The company raised its full-year base business revenue guidance for the second time this year, citing robust demand for Biktarvy and HIV prevention products.

“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”

Daniel O’Day, Gilead’s Chairman and Chief Executive Officer

“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”

Daniel O’Day, Gilead’s Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.